Short-acting Beta Agonists Market Outlook:
Short-acting Beta Agonists Market size was valued at USD 868.04 million in 2025 and is likely to cross USD 2.11 billion by 2035, expanding at more than 9.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of short-acting beta agonists is assessed at USD 940.69 million.
The escalating prevalence of respiratory disorders worldwide is propelling the market’s growth. With 454.6 million cases (417.4–499.1) worldwide, chronic respiratory disorders ranked as the third most common cause of mortality in 2019. They were responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) worldwide. As conditions like asthma and chronic obstructive pulmonary disease(COPD) become more widespread, the demand for quick-relief medications, such as SABAs, continues to surge. As observed by Research Nester analysts, globally, the prevalence of COPD was predicted to be 10.6% in 2020 for both males and females, or 480 million cases. This driver is fuelled by environmental factors, lifestyle changes, and an aging population, necessitating effective bronchodilators for immediate symptom relief. As a result, pharmaceutical companies are witnessing increased demand for SABAs, positioning them as a pivotal solution in addressing the rising global burden of respiratory diseases.
In addition, when it comes to death rates, chronic obstructive pulmonary disease (COPD) is ranked third worldwide. The increasing prevalence of lung illnesses worldwide is predicted to drive short-acting beta agonists market expansion. People who currently reside in or were raised in urban regions are more prone to experience these illnesses.
